US 9,810,697 B2
Protein and lipid biomarkers providing consistent improvement to the prediction of Type 2 diabetes
Michael P. McKenna, Branford, CT (US); and Steve M. Watkins, Sacramento, CA (US)
Assigned to True Health IP, LLC, Frisco, TX (US)
Filed by True Health Diagnostics, LLC, Frisco, TX (US)
Filed on Nov. 18, 2015, as Appl. No. 14/945,200.
Application 14/945,200 is a continuation of application No. 13/504,720, granted, now 9,217,747, issued on Dec. 22, 2015, previously published as PCT/US2010/054398, filed on Oct. 28, 2010.
Claims priority of provisional application 61/256,302, filed on Oct. 29, 2009.
Prior Publication US 2017/0003297 A1, Jan. 5, 2017
Int. Cl. G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); G01N 33/66 (2006.01); G01N 33/92 (2006.01); G06F 19/00 (2011.01)
CPC G01N 33/6893 (2013.01) [G01N 33/66 (2013.01); G01N 33/92 (2013.01); G06F 19/3437 (2013.01); G01N 2800/042 (2013.01); G01N 2800/50 (2013.01)] 30 Claims
 
1. A method of treating a subject having an elevated risk for developing a diabetic condition, the method comprising:
(a) obtaining biomarker measurement data for an individual, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual; wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the group consisting of: adiponectin, C-reactive protein, ferritin, glucose, hemoglobin A1c (HbA1c), insulin, and interleukin-2-receptor alpha (IL2RA) and (iii) at least one lipid metabolite selected from the group consisting of: cholesteryl palmitoleate (CE16:1n7), cholesteryl homo gamma linoleate (CE20:3n6), cholesteryl linoleate (CE18:2n6), cholesteryl palmitate (CE16:0), cholesteryl petroselinate (CE18:1n9), 1-linoleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18:2n6), and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LY18:1n7 and LY18:1n9);
(b) identifying the individual as having an elevated risk for developing a diabetic condition based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data; and
(c) treating the individual identified as having an elevated risk for developing a diabetic condition with a treatment regimen to delay or prevent the onset of diabetes.